The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with ...
Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...
The approval comes less than a year Bristol Myers Squibb paid $14 billion to acquire the developer of the drug, Karuna ...
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
The US Food and Drug Administration has approved Cobenfy, which one researcher referred to as a "game changer" for ...
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...
Christopoulos, Dean of the Faculty of Pharmaceutical Sciences at Monash University, is at the centre of a significant ...
In three medium-to large-sized clinical trials, Karuna showed that treatment with Cobenfy significantly relieved ...